Overall, most patients had more recent year at diagnosis from 2011 to 2015 (52%), stage II cancer (45.9%), infiltrating ductal carcinoma (84.3%), HR+/HER2– expression (59.4%), surgery combined with adjuvant therapy (78.5%), treatment delay ≤ 30 days (81.9%), normal BMI (48.0%), never cigarette smoking status (95.3%), and never alcohol drinking status (94.7%). The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.